Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET known ✓ | P07949 | 1/20 | 0.44 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FES | P07332 | 1/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23855082 | 1.00 | NAPRT (0.54) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL31358964 | 1.00 | NAPRT (0.54) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL31358963 | 1.00 | NAPRT (0.54) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL16198319 | 0.98 | NAPRT (0.56) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL30120603 | 0.98 | NAPRT (0.56) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL7280697 | 0.81 | NAPRT (0.61) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL3253168 | 0.80 | NAPRT (0.74) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL30195679 | 0.79 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL28975712 | 0.79 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL28295321 | 0.79 | L3MBTL1 (0.54) | EPHX2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527187-B | Asymmetric preparation method of nicotine | 凯特立斯（深圳）科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| EP-3925955-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2021-12-22 | — | — | EP | claimed |
| WO-2021212880-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | 凯特立斯（深圳）科技有限公司 (CN) | 2021-10-28 | — | — | WO | claimed |
| CN-113527187-A | Asymmetric preparation method of nicotine | 凯特立斯（深圳）科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | FEELLIFE HEALTH INC. (CN) | 2021-09-30 | — | — | US | claimed |
| CN-112876454-A | Preparation method of artificially synthesized (R, S) -nicotine salt | 深圳梵活生命科学股份有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-107011321-A | A kind of preparation method of artificial synthesized raceme nicotine | 华健 | 2017-08-04 | — | — | CN | claimed |
| CN-113527187-B | Asymmetric preparation method of nicotine | 凯特立斯（深圳）科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117000304-A | Application of cyclic quaternary ammonium base in preparation of racemic nicotine | 国家烟草质量监督检验中心 | 2023-11-07 | — | — | CN | disclosed |
| CN-114702475-A | Synthesis process of single-configuration nicotine | 大连天源基化学有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3925955-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2021-12-22 | — | — | EP | disclosed |
| EP-3925955-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021212880-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | 凯特立斯（深圳）科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113527187-A | Asymmetric preparation method of nicotine | 凯特立斯（深圳）科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | FEELLIFE HEALTH INC. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | FEELLIFE HEALTH INC. (CN) | 2021-09-30 | — | — | US | disclosed |
| CN-112876454-A | Preparation method of artificially synthesized (R, S) -nicotine salt | 深圳梵活生命科学股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112876454-A | Preparation method of artificially synthesized (R, S) -nicotine salt | 深圳梵活生命科学股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107011321-A | A kind of preparation method of artificial synthesized raceme nicotine | 华健 | 2017-08-04 | — | — | CN | disclosed |
| WO-2014174505-A2 | A PROCESS FOR THE PREPARATION OF NICOTINE COMPRISING THE ENZYMATIC REDUCTION OF 4- (METHYLAMINO) -1- (PYRIDIN-3- YL) BUTAN-1-ONE | PERRIGO API LTD. (IL) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | SRM, BRSK2, BRSK1 | RET 465/4885FLT4 3823/4885NAPRT 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.